FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated